# A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.

> **NCT00651365** · PHASE1 · TERMINATED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 14 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** JNJ-38877605

## Key facts

- **NCT ID:** NCT00651365
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Early termination due to increase in serum creatinine levels and minimal PD activity.
- **Last updated:** 2013-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651365, "A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00651365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*